Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Urothelial cancers from Endoxan].

J P Dumas, B Roulet, P Colombeau

    Journal D'Urologie
    |January 1, 1984
    PubMed
    Summary

    Long-term Endoxan treatment may increase the risk of bladder cancer. This finding suggests limiting its use and enhancing urological monitoring for patients receiving this chemotherapy agent.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Not Available].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015
    Same author

    [Magnetic resonance imaging for delineation of prostate in radiotherapy: monocentric experience and review of literature].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2012
    Same author

    [Study of urinary continence after radical prostatectomy. Comparison between laparoscopic and retropubic prostatectomy based on a series of 251 cases].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2008
    Same author

    Limitation of exercise capacity in nucleoside-treated HIV-infected patients with hyperlactataemia.

    HIV medicine·2007
    Same author

    [Benign prostatic hyperplasia (BPH) and metabolic syndrome: a single comorbidity].

    Annales d'urologie·2006
    Same author

    Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.

    European urology·2005

    Area of Science:

    • Oncology
    • Urology
    • Pharmacology

    Background:

    • Cyclophosphamide (Endoxan) is a widely used chemotherapeutic agent.
    • Its potential role in secondary malignancies, particularly urothelial carcinoma, warrants investigation.

    Observation:

    • A case report details bladder carcinoma in a patient with a 20-year history of Endoxan treatment.
    • This observation aligns with 35 previously published cases linking Endoxan to urothelial carcinoma.

    Findings:

    • The cumulative evidence strongly suggests a causal relationship between Endoxan therapy and the development of urothelial carcinoma.
    • A significant association exists between prolonged cyclophosphamide exposure and bladder cancer etiology.

    Implications:

    • Prescribing practices for Endoxan may require re-evaluation and potential limitations.
    • Enhanced urological surveillance protocols are recommended for patients undergoing long-term Endoxan treatment.
    • Further research into the oncogenic mechanisms of alkylating agents is warranted.

    Related Experiment Videos